Activin A Monoclonal Antibody (H9), Invitrogen™
Mouse Monoclonal Antibody
Manufacturer: Fischer Scientific
The price for this product is unavailable. Please request a quote
Antigen
Activin A
Concentration
1 mg/mL
Classification
Monoclonal
Form
Liquid
Regulatory Status
RUO
Formulation
PBS with 50% glycerol and 0.05% ProClin 300
Gene Alias
activin A; activin beta-A chain; BMP7; BMP-7; Bone morphogenetic protein 7; EDF; Eptotermin alfa; erythroid differentiation factor; erythroid differentiation protein; follicle-stimulating hormone-releasing protein; FRP; FSH-releasing protein; INHB; Inhba; inhibin B subunit; inhibin beta A chain; inhibin beta A protein; inhibin beta A subunit; inhibin beta-A; inhibin beta-A-subunit; inhibin beta-subunit; inhibin subunit beta A; inhibin, beta A; inhibin, beta A (activin A, activin AB alpha polypeptide); Inhibin, beta-1; OP1; OP-1; Osteogenic protein 1; unnamed protein product
Gene Symbols
Inhba
Isotype
IgG1 κ
Purification Method
Affinity chromatography
Product Type
Antibody
Clone
H9
Applications
Immunohistochemistry (Paraffin), Western Blot
Conjugate
Unconjugated
Host Species
Mouse
Target Species
Human
Gene Accession No.
P08476
Gene ID (Entrez)
3624
Immunogen
Gly311-Ser426 (Accession P08476), with N-terminal His Tag
Primary or Secondary
Primary
Content And Storage
-20°C
Gene
Inhba
Related Products
Description
- Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins
- Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors
- These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity
- Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors
- Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors
- Activin A mutations are associated with fibrodysplasia ossificans progressive.